



[Go to Product page](#)

Datasheet for ABIN7488036

Recombinant anti-PCSK9 (Bococizumab Biosimilar) antibody

Overview

Quantity:	100 µg
Target:	PCSK9 (Bococizumab Biosimilar)
Reactivity:	Human
Host:	Mammalian Cells
Antibody Type:	Recombinant Antibody
Clonality:	Monoclonal
Application:	ELISA

Product Details

Purpose:	Bococizumab Biosimilar - Anti-PCSK9, NARC1, PC9 mAb
Isotype:	IgG2
Characteristics:	Antibody Type: IgG2-kappa
Grade:	Research Grade

Target Details

Target:	PCSK9 (Bococizumab Biosimilar)
Target Type:	Biosimilar
Background:	PF-04950615,RN-316

Bococizumab is a monoclonal antibody that was developed by Pfizer targeting proprotein convertase subtilisin kexin type 9 (PCSK9). Bococizumab has been investigated for the treatment and prevention of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia,

Target Details

Cardiovascular Disease, and Heterozygous Familial Hypercholesterolemia.

CAS-No: 1407495-02-6

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS pH 7.5

Storage: -80 °C

Storage Comment: store at -80°C